MedPath

Body Composition Analysis and Time to Emergence From Remimazolam

Conditions
Remimazolam
Body Composition
Registration Number
NCT05512559
Lead Sponsor
Samsung Medical Center
Brief Summary

Remimazolam is a novel general anesthetic drug. The time to emergence from remimazolam-based general anesthesia is variable among patients, but little is known about the risk factors for delayed emergence. We believe that information from body composition analysis may be helpful in understanding which patients are more likely to show delayed emergence from remimazolam.

Detailed Description

Not available

Recruitment & Eligibility

Status
ENROLLING_BY_INVITATION
Sex
All
Target Recruitment
90
Inclusion Criteria
  • Adult ASA I-III patients undergoing cerebral aneurysm coil embolization under general anesthesia using remimazolam
Exclusion Criteria
  • Patients with preoperative mental change, hemodynamic instability, hemodialysis, heart failure, hypoalbuminemia, pregnancy

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
emergence timeat the time of emergence

relationship between body composition analysis information and time to emergence after discontinuing remimazolam infusion.

Secondary Outcome Measures
NameTimeMethod
time to loss of consciousnessat the time of induction

relationship between body composition analysis information and time to loss of consciousness after starting remimazolam infusion.

hypotensionfrom induction to emergence of anesthesia

relationship between body composition analysis information and hypotensive event during anesthesia

Trial Locations

Locations (1)

Samsung Medical Center, Sungkyunkwan University, School of Medicine

🇰🇷

Seoul, Korea, Republic of

Samsung Medical Center, Sungkyunkwan University, School of Medicine
🇰🇷Seoul, Korea, Republic of

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.